Intercept to Present at Upcoming Investor Conference

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:

• J.P. Morgan 2017 Healthcare Conference on January 11, 2017 at 5:00 p.m. Pacific Time

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

For more information about
Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]

Media inquiries: [email protected]

Investor inquiries: [email protected]

Source: Intercept Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Green Building Materials Market Projected to Surpass USD 1059.03 Billion by 2031 Driven By Surging demand for sustainable construction fuels exponential growth
• Former CEO of Aculon and SVP/GM of TaylorMade Golf Joins CEO Coaching International
• Amazing April: Made-in-China.com Buzzes with Buyer Activity